Furthermore, it suggests in this setting that TIM-3 may have an inhibitory role for NK cells in OAC and that cancer cell mediated decreases in the expression of this marker may facilitate enhanced NK cell function in both the cisplatin-sensitive and resistant OAC tumour. The gene discussed is HAVCR2; the disease is neoplasm.